Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87


The use of protein phosphatase 2A activators in combination therapies for pancreas cancer.

Allen-Petersen BL, Sears RC.

Oncotarget. 2019 Mar 12;10(21):2008-2009. doi: 10.18632/oncotarget.26772. eCollection 2019 Mar 12. No abstract available.


Co-expression of FOXL1 and PP2A inhibits proliferation inducing apoptosis in pancreatic cancer cells via promoting TRAIL and reducing phosphorylated MYC.

Li Y, Yu D, Sheng W, Song H, Li Y, Dong M.

Oncol Rep. 2016 Apr;35(4):2198-206. doi: 10.3892/or.2016.4592. Epub 2016 Jan 25.


Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression.

Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL.

Nat Commun. 2018 Mar 13;9(1):1047. doi: 10.1038/s41467-018-03327-4. Erratum in: Nat Commun. 2018 Sep 17;9(1):3830.


Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.

Farrell AS, Allen-Petersen B, Daniel CJ, Wang X, Wang Z, Rodriguez S, Impey S, Oddo J, Vitek MP, Lopez C, Christensen DJ, Sheppard B, Sears RC.

Mol Cancer Res. 2014 Jun;12(6):924-39. doi: 10.1158/1541-7786.MCR-13-0542. Epub 2014 Mar 25.


Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.

Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, Pelz KR, Morton JP, Sansom OJ, Lopez CD, Sheppard B, Christensen DJ, Ohlmeyer M, Narla G, Sears RC.

Cancer Res. 2019 Jan 1;79(1):209-219. doi: 10.1158/0008-5472.CAN-18-0717. Epub 2018 Nov 2.


Activating protein phosphatase 2A (PP2A) enhances tristetraprolin (TTP) anti-inflammatory function in A549 lung epithelial cells.

Rahman MM, Rumzhum NN, Hansbro PM, Morris JC, Clark AR, Verrills NM, Ammit AJ.

Cell Signal. 2016 Apr;28(4):325-34. doi: 10.1016/j.cellsig.2016.01.009. Epub 2016 Jan 26.


Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.

Cirak Y, Varol U, Atmaca H, Kisim A, Sezgin C, Karabulut B, Uzunoglu S, Uslu R, Karaca B.

BJU Int. 2012 Dec;110(11 Pt C):E1147-54. doi: 10.1111/j.1464-410X.2012.11392.x. Epub 2012 Aug 9.


Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.

Khanna A, Pimanda JE, Westermarck J.

Cancer Res. 2013 Nov 15;73(22):6548-53. doi: 10.1158/0008-5472.CAN-13-1994. Epub 2013 Nov 7. Review.


Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J, Langer EM, Christensen DJ, Sears RC.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9157-62. doi: 10.1073/pnas.1317630111. Epub 2014 Jun 9.


Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia.

Ramaswamy K, Spitzer B, Kentsis A.

Front Oncol. 2015 Feb 2;5:16. doi: 10.3389/fonc.2015.00016. eCollection 2015. Review.


Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.

Kim MO, Choe MH, Yoon YN, Ahn J, Yoo M, Jung KY, An S, Hwang SG, Oh JS, Kim JS.

Biochem Pharmacol. 2017 Nov 15;144:78-89. doi: 10.1016/j.bcp.2017.08.009. Epub 2017 Aug 13.


PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. doi: 10.1126/scitranslmed.aaq1093.


Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family (PP2A(C), PP4(C), and PP6(C)) and analysis of the interaction of PP2A(C) with alpha4 protein.

Kloeker S, Reed R, McConnell JL, Chang D, Tran K, Westphal RS, Law BK, Colbran RJ, Kamoun M, Campbell KS, Wadzinski BE.

Protein Expr Purif. 2003 Sep;31(1):19-33.


Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer.

Kauko O, Westermarck J.

Int J Biochem Cell Biol. 2018 Mar;96:157-164. doi: 10.1016/j.biocel.2018.01.005. Epub 2018 Jan 31. Review.


Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.

Perrotti D, Neviani P.

Cancer Metastasis Rev. 2008 Jun;27(2):159-68. doi: 10.1007/s10555-008-9119-x. Review.


Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo.

Lambrecht C, Libbrecht L, Sagaert X, Pauwels P, Hoorne Y, Crowther J, Louis JV, Sents W, Sablina A, Janssens V.

Oncogene. 2018 Jan 25;37(4):544-552. doi: 10.1038/onc.2017.350. Epub 2017 Oct 2.


Protein phosphatase 2A: a target for anticancer therapy.

Perrotti D, Neviani P.

Lancet Oncol. 2013 May;14(6):e229-38. doi: 10.1016/S1470-2045(12)70558-2. Review.


Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720.

Baldacchino S, Saliba C, Petroni V, Fenech AG, Borg N, Grech G.

EPMA J. 2014 Jan 25;5(1):3. doi: 10.1186/1878-5085-5-3.


Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.

Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, Moore A, Ashman LK, Skelding KA, Enjeti A, Verrills NM.

Oncotarget. 2016 Jul 26;7(30):47465-47478. doi: 10.18632/oncotarget.10167.

Supplemental Content

Support Center